Login to Your Account



Agios cues up PK-deficiency fighter AG-348 with first phase I test

By Michael Fitzhugh
Staff Writer

Thursday, April 17, 2014
in_the_clinic.jpg

Agios Pharmaceuticals Inc. has started a phase I dosing study of its lead candidate for inborn errors of metabolism, AG-348. The experimental treatment for pyruvate kinase (PK) deficiency, a rare inherited metabolic disorder, could help rapidly advance the drug toward a proof-of-concept test in target patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription